MaaT Pharma to Hold Annual General Meeting on May 28, 2024 Lyon, France, April 22nd 2024 –7.30 am CET – MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotech company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for patients with cancer, informs its shareholders that the [...]
MaaT Pharma Presents Positive 18-month Data for MaaT013 Showing a Clear Overall Survival Advantage in aGvHD from the Early Access Program at the 2024 EBMT Event [fancy-ul icon_type="standard_dash" color="Accent-Color" alignment="left" spacing="default"] Positive efficacy and safety results in 140 patients treated with MaaT013 in acute graft-versus-host disease (aGvHD) as part of the MaaT Pharma Early Access [...]
MaaT Pharma to Hold Annual General Meeting on May 28, 2024 Lyon, France, April 22nd 2024 –7.30 am CET – MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotech company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for patients with cancer, informs its shareholders that the [...] 